1. Home
  2. MRM vs CALC Comparison

MRM vs CALC Comparison

Compare MRM & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MEDIROM Healthcare Technologies Inc.

MRM

MEDIROM Healthcare Technologies Inc.

N/A

Current Price

$0.33

Market Cap

7.6M

ML Signal

N/A

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

N/A

Current Price

$1.40

Market Cap

7.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MRM
CALC
Founded
2000
2011
Country
Japan
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.6M
7.6M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
MRM
CALC
Price
$0.33
$1.40
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $38.00
AVG Volume (30 Days)
★ 374.2K
78.1K
Earning Date
11-13-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$32.01
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.25
$0.44
52 Week High
$2.33
$72.00

Technical Indicators

Market Signals
Indicator
MRM
CALC
Relative Strength Index (RSI) 26.26 44.93
Support Level $0.25 $1.00
Resistance Level $1.34 $2.31
Average True Range (ATR) 0.04 0.19
MACD 0.01 0.12
Stochastic Oscillator 40.45 49.40

Price Performance

Historical Comparison
MRM
CALC

About MRM MEDIROM Healthcare Technologies Inc.

MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Share on Social Networks: